StoneX Group’s 9 Meters Biopharma NMTR Stock Holding History

StoneX Group’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000	Closed	-$19.6K	–	667
2021 Q4	$19.6K	Buy	+1,000	New	+$22.4K	﹤0.01%	558

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

StoneX Group's NMTR Position: Q1 2022 in Review

StoneX Group sold out of 9 Meters Biopharma (NMTR) in Q1 2022, closing a stake of 1,000 shares — an estimated $19.6K sold.

StoneX Group first reported a position in NMTR in Q4 2021 and held it in 1 quarter. The position peaked at $19.6K in Q4 2021. 101 funds tracked by Wall St. Rank hold NMTR as of Q1 2022.

StoneX Group reported no remaining 9 Meters Biopharma position as of Q1 2022 after selling out during the quarter.
StoneX Group sold 1,000 9 Meters Biopharma shares in Q1 2022, an estimated $19.6K.
StoneX Group first reported a position in 9 Meters Biopharma in Q4 2021 and held it in 1 quarter.
StoneX Group's 9 Meters Biopharma position peaked at $19.6K in Q4 2021.
101 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q1 2022.

Based on StoneX Group's 13F filing for Q1 2022, filed 11 May 2022.